Scott Gottlieb Quotes


In the U.S, Zika outbreaks are hopefully going to be easy to isolate. The biggest threat is likely to be from the fear Zika sows, especially among expectant moms.


Citations

Gottlieb, Scott. "How To Prepare For The Next Zika." Forbes, 2016.

Related Quotes

Microcephaly is a condition where newborn children have very small heads, the the brain cannot develop sufficiently to normally function. Almost all Americans had heard about microcephaly and the Zika virus that caused the condition in pregnant women, but it has been in South America, Latin America and Puerto Rico. When people have friends, coworkers and family who have a serious medical condition, they believe it is a serious problem that needs society’s attention. At the time Fauci made this statement Americans on the mainland had not yet seen any cases, Zika was unfortunately not taken seriously enough.


Sachs was commenting on the tendency of some to blame all the problems of Africa on corruption and bad governance.


Virtually every spread of virus caused disease that has occurred in the late 20th century and onward was spread to different regions by people, who in an age of rapid travel, are what the public health scientists call “the vectors” — the carriers of the disease. In earlier times it was animals like rats who spread the disease.


Scott Gottlieb
Scott Gottlieb
  • Born: June 11, 1972
  • Nationality: American
  • Profession: Public Servant

Scott Gottlieb is an American physician and investor who served as the 23rd commissioner of the Food and Drug Administration (FDA) from 2017 until April 2019. He is presently a resident fellow at the conservative think tank the American Enterprise Institute (AEI), a partner at the venture capital firm New Enterprise Associates (NEA), a member of the board of directors of drug maker Pfizer, Inc, a member of the board of directors of Illumina, Inc., and a contributor to the cable financial news network CNBC. Before becoming FDA commissioner, he was a clinical assistant professor at New York University School of Medicine, the FDA deputy commissioner for medical and scientific affairs, a venture partner with New Enterprise Associates, a member of the policy board of the Leukemia & Lymphoma Society, a senior official at the Centers for Medicare and Medicaid Services, and a member of the Federal Health Information Technology Policy Committee, which advises the United States Department of Health and Human Services on healthcare information technology. He was previously a resident fellow at AEI from 2007 to 2017 prior to joining the FDA as commissioner in May 2017.